Shelley Force Aldred and Nathan Trinklein, co-founders of Rondo Therapeutics, on the opportunity with bispecific antibodies for cancer.

The Long Run with Luke Timmerman

Ep151: Shelley Force Aldred and Nathan Trinklein on Bispecific Antibodies for Cancer

"The Long Run" Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous. Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.

About

The Long Run with Luke Timmerman